<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) refers to an abnormal change (<z:mpath ids='MPATH_160'>metaplasia</z:mpath>) in the cells of the inferior portion of the esophagus </plain></SENT>
<SENT sid="1" pm="."><plain>About 10% of patients with symptomatic <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) have BE </plain></SENT>
<SENT sid="2" pm="."><plain>In some cases, BE develops as an advanced stage of erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The risk of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> appears to be increased in patients with BE </plain></SENT>
<SENT sid="4" pm="."><plain>The only way to diagnose BE is by endoscopy and histology </plain></SENT>
<SENT sid="5" pm="."><plain>Some studies suggest that intensive treatment of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with effective acid suppression can reduce the amount of abnormal lining in the esophagus </plain></SENT>
<SENT sid="6" pm="."><plain>It is not clear whether such treatment also prevents <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Generally, the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> starts out as <z:mp ids='MP_0002038'>carcinoma</z:mp> of the esophagus on the surface, and then invades the surrounding tissue </plain></SENT>
<SENT sid="8" pm="."><plain>Surgery offers the best chance of long-term survival </plain></SENT>
<SENT sid="9" pm="."><plain>There are many events that occur in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> that lead to the development of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and most of them appear to occur early, before high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> develops </plain></SENT>
<SENT sid="10" pm="."><plain>No one knows what the late events are and how cells acquire the ability to leave their <z:mpath ids='MPATH_458'>normal</z:mpath> growth boundaries </plain></SENT>
<SENT sid="11" pm="."><plain>It is now widely accepted that the development of most <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> is due to something called genomic or genetic instability </plain></SENT>
<SENT sid="12" pm="."><plain>The aim of this review is to show BE pathology in its progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> looking for new biomarkers to distinguish between BE -<z:mpath ids='MPATH_589'>dysplasia</z:mpath> (low grade and high grade)- <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (<z:chebi fb="49" ids="35181">ADC</z:chebi>) and to characterize the <z:chebi fb="49" ids="35181">ADC</z:chebi>, giving more hope for its treatment </plain></SENT>
</text></document>